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Abstract 1	
INTRODUCTION: Identifying at what point atrophy rates first change in Alzheimer’s 2	
disease is important for informing design of presymptomatic trials. 3	
METHODS: Serial T1-weighed MRI scans of 94 participants (28 non-carriers, 66 4	
carriers) from the Dominantly Inherited Alzheimer Network (DIAN) were used to 5	
measure brain, ventricular and hippocampal atrophy rates. For each structure, non-6	
linear mixed effects models estimated the change-points when atrophy rates deviate 7	
from normal and the rates of change before and after this point. 8	
RESULTS: Atrophy increased after the change-point, which occurred 1-1.5 years 9	
(assuming a single step change in atrophy rate) or 3-8 years (assuming gradual 10	
acceleration of atrophy) before expected symptom onset. At expected symptom 11	
onset, estimated atrophy rates were at least 3.6 times those before the change-point. 12	
DISCUSSION: Atrophy rates are pathologically increased up to seven years before 13	
“expected onset”. During this period, atrophy rates may be useful for inclusion and 14	
tracking of disease progression. 15	
 16	
 17	
Keywords: Longitudinal, Atrophy, Alzheimer's disease, Dementia, Autosomal 18	
dominant, Neuroimaging, MRI, Boundary Shift Integral, Non-linear modeling, 19	
Change-point  20	
	 4	
1. Background  1	
Testing potentially disease-modifying treatments for Alzheimer’s disease (AD) during 2	
the preclinical phase [1] presents challenges of recruitment and staging of 3	
asymptomatic individuals, as well as determining suitable measures for assessing 4	
disease modification. One recruitment strategy is to study members of families 5	
known to carry a pathogenic mutation in a gene – presenilin 1 (PSEN1), presenilin 2 6	
(PSEN2) or amyloid precursor protein (APP) – that causes autosomal dominant AD 7	
(ADAD). These mutations have almost 100% penetrance and ~50% of at-risk 8	
individuals are carriers. ADAD typically has an early and relatively predictable age at 9	
symptom onset [2,3]. The Dominantly Inherited Alzheimer Network (DIAN) is a 10	
multicentre observational study of individuals at risk of, or affected by, ADAD. DIAN 11	
performs longitudinal assessments of imaging, fluid biomarkers, and cognitive 12	
function, which reflect pathological features in ADAD [4] and sporadic AD [5]. In 13	
particular, cerebral atrophy measures derived from volumetric magnetic resonance 14	
imaging (MRI) are used as biomarkers of neurodegeneration and as outcome 15	
measures in trials [6].  16	
 17	
Longitudinal data from presymptomatic ADAD individuals provide a unique 18	
opportunity to determine when atrophy rates begin to diverge from normal. Previous 19	
cross-sectional, or small longitudinal studies report a wide range of estimates of this 20	
point of divergence: from 10 years before [4,7] to 7 years after [8] expected clinical 21	
onset (as determined by the affected parent’s age at onset).  22	 																																																								
 Abbreviations:	DIAN	=	Dominantly	Inherited	Alzheimer	Network;	ADAD	=	autosomal	dominantly	inherited	familial	AD;	PSEN1	=	presenilin	1;	PSEN2	=	presenilin	2;	APP	=	amyloid	precursor	protein;	EAO	=	expected	age	at	onset;	EYO	=	estimated	years	to	expected	symptom	onset;	NC	=	mutation	non-carriers;	pMut+	=	presymptomatic	mutation	carriers;	qMut+	=	questionably	or	mildly	symptomatic	mutation	carriers;	sMut+	=	overtly	symptomatic	mutation	carriers.		
	 5	
 1	
We used serial MRI data from DIAN to model cerebral atrophy rates during 2	
presymptomatic and early symptomatic stages of ADAD. We assessed whole brain 3	
and hippocampal atrophy and ventricular expansion, three well-established imaging 4	
measures used as exploratory endpoints in clinical trials [6]. We hypothesize that 5	
presymptomatic carriers have similar atrophy rates to non-carriers up until a ‘change-6	
point’ when the biomarker starts to diverge from normal. This hypothesis is 7	
consistent with models of sporadic AD [5] that assume a sigmoidal trajectory, and 8	
cross-sectional findings from the DIAN cohort [4,7]. We used two non-linear mixed 9	
effects models (Supplementary Appendix A) to estimate the timing of change-points 10	
relative to expected symptom onset, and atrophy rates before and after these 11	
change-points. The first model assumes that the atrophy rate undergoes a single 12	
‘step change’ to a new, stable value; whereas the second model assumes a ‘gradual 13	
acceleration’ in atrophy rate after the change-point. These models help characterize 14	
when therapeutic effects on brain atrophy could potentially be observed in 15	
presymptomatic ADAD and could help focus future sample size calculations for 16	
upcoming prevention trials. 17	
 18	
2. Methods 19	
2.1 Participants and Procedures 20	
All participants were members of DIAN [9], and details of participating sites are 21	
available (http://dian-info.org/). The study received prior approval from appropriate 22	
Institutional Review Boards and Ethics Committees at each site. Informed consent 23	
was obtained from all participants. 24	
 25	
	 6	
Genotyping was performed to determine the presence of an ADAD mutation for each 1	
at-risk participant. A semi-structured interview assessed the expected age at onset 2	
(EAO), based on when the affected parent first showed progressive cognitive 3	
decline. Expected years to symptom onset (EYO) is the difference between age at 4	
scan and EAO [3]. Negative values indicate years before expected onset and 5	
positive values years after. 6	
 7	
At the sixth data freeze (July 2013), there were 102 participants with two or more 8	
MRI scans available and complete data (mutation status, age, EAO, and global 9	
Clinical Dementia Rating (CDR) score [10]).  10	
 11	
2.2 Volumetric MRI  12	
Volumetric T1-weighted scans were acquired on 3 Tesla MRI scanners using 13	
Alzheimer's Disease Neuroimaging Initiative (ADNI) standardized protocols [11] and 14	
corrected for intensity inhomogeneity [12]. Whole brain and hippocampal regions 15	
were automatically segmented [13–15]. Lateral ventricles were delineated semi-16	
automatically by an expert rater. Baseline volumetric measures were corrected for 17	
total intracranial volume (TIV), calculated using an automated technique [16]. For 18	
each structure, volume change was directly measured using a group-wise 19	
implementation [17–19] of the Boundary Shift Integral (BSI) [20] to ensure 20	
longitudinal consistency. A trained image analyst, blinded to participants’ mutation 21	
and clinical status, reviewed all raw and processed images. 22	
 23	
2.3 Clinical Classification 24	
	 7	
Participants were classified into four groups, based on mutation status, global CDR 1	
score, and actual age at onset (where this had occurred), determined by Uniform 2	
Data Set form B9, “Clinical Judgment of symptoms” [21]:  3	
 4	
• Mutation non-carriers (NC); our control group.  5	
• Presymptomatic mutation carriers (pMut+);	included mutation carriers with 6	
a global CDR score of 0 at both their first two visits.  7	
• Questionably or mildly symptomatic mutation carriers (qMut+); included 8	
participants with at least one global CDR score of 0.5 during their first two 9	
visits, with the other visit being either 0 or 0.5. We excluded from this group 10	
participants who had a reported onset more than four years before study 11	
entry. 12	
• Overtly symptomatic mutation carriers (sMut+); included participants with 13	
a CDR score of 1.0 or greater at either (or both) of their first two visits or who 14	
were more than four years after reported onset at study entry.  15	
 16	
Eight participants were excluded from the analysis: seven (one NC, four pMut+, one 17	
qMut+, one sMut+) were identified during initial visual review of the image data and 18	
excluded due to non-Alzheimer’s pathology (e.g. infarct, neoplasm), imaging 19	
artifacts, or acquisition-related changes likely to result in unreliable atrophy 20	
measures. An additional participant (qMut+) was excluded due to moderate motion 21	
artefact on follow-up imaging and implausible growth in brain and hippocampi. As 22	
part of the sensitivity analysis, we re-ran the model including this participant 23	
(Supplementary Appendix B). 24	
 25	
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Two participants who initially satisfied the qMut+ criteria were retrospectively re-1	
classified as sMut+, as both participants had consistent evidence of cognitive decline 2	
over a sustained period.  3	
 4	
Our final sample therefore included 94 participants: 24 pMut+, 18 qMut+, 24 sMut+, 5	
and 28 NC. Of the 66 carriers, 54 had mutations in PSEN1, three in PSEN2, and 6	
nine in APP. There were 66 participants with two MR scans, 20 with three, and eight 7	
with four scans. The scan interval between baseline to follow-up ranged from 0.9 to 8	
3.3 years, and was independent of carrier status or clinical severity. Two participants 9	
(one qMut+ and one sMut+) had inadequate image quality for analyses involving 10	
hippocampi. 11	
 12	
2.4 Statistical analysis 13	
To compare baseline values between each of the three mutations groups (pMut+, 14	
qMut+, sMut+) and the non-carrier group, ANOVA models were used for age, EYO, 15	
and TIV, while logistic regression was used for APOE e4 positivity and sex. A 16	
generalized least squares linear regression model that allows different group-specific 17	
residual variances was used to compare baseline volumes (standardized to mean 18	
TIV) between each of the three carrier groups and non-carriers.  19	
 20	
The change-point model [22–24] was used to explore brain, ventricular and 21	
hippocampal atrophy rates (Supplementary Appendix A provides a detailed model 22	
description). As the focus of our study was the presymptomatic and earliest 23	
symptomatic stages of ADAD, the model included non-carriers (NC), 24	
presymptomatic, and questionably symptomatic carriers (pMut+/qMut+). 25	
	 9	
 1	
Figure 1 provides a schematic representation of the ‘step change’ and ‘gradual 2	
acceleration’ change-point models. In both, β represents the shared atrophy rate for 3	
NC and pMut+/qMut+ groups before the change-point, which takes place δ years 4	
before or after the EAO. Due to limited data, δ (for a specific brain structure) was 5	
assumed to be the same for all pMut+/qMut+ individuals. 6	
 7	
For the ‘step change’ model, γ is the change in atrophy rate for the pMut+/qMut+ 8	
group after the change-point. In the ‘gradual acceleration’ model, the atrophy rate for 9	
the pMut+/qMut+ group accelerates after the change-point by a value of 2γ per year. 10	
With each model, we estimated β, γ and δ for each region, and using these we 11	
estimated atrophy rates at various points before and after EAO.  12	
 13	
Our change-point model was not designed to estimate atrophy rates several years 14	
after symptom onset; to do so risked distorting a model that was designed to focus 15	
on the progression from early changes to clinical symptoms. Thus, a separate linear 16	
mixed-effects random-slopes model (with no change-point) was used to model 17	
atrophy rates of the sMut+ group, assuming all observations were after the change-18	
point.  19	
 20	
The change-point models are non-linear extensions of a previously described linear 21	
mixed-effects random-slopes model [25] (Supplementary Appendix A). Atrophy 22	
measures were log-transformed to provide symmetric approximations of percentage 23	
change from baseline. The change-point models were implemented using SAS 24	
	 10	
(version 9.4) procedure NLMIXED, which simultaneously estimated β, γ and δ. 1	
Robust estimates of uncertainty for these coefficients were obtained through 2	
bootstrapping [26,27], with 10,000 replicates and using bias corrected and 3	
accelerated (BCa) 95% confidence intervals. Sensitivity of the estimates and 4	
confidence intervals to outliers was explored (see Supplementary Appendix B).  5	
 6	
3. Results 7	
Table 1 summarizes demographic and clinical data. The sMut+ group was, as 8	
expected, older than the non-carriers, with smaller brain and hippocampal volumes, 9	
and larger ventricular volumes (all TIV-adjusted), reflecting pathological losses and 10	
larger TIV, which likely reflects the higher (albeit statistically non-significant) 11	
proportion of males in this group. The qMut+ group had smaller hippocampal 12	
volumes and larger ventricular volumes compared to non-carriers, while the preMut+ 13	
group just had smaller right hippocampal volumes. 14	
 15	
Table 2 shows the change-point model results for each structure. In the ‘step 16	
change’ model, the pre-change atrophy rate (β) was statistically significant in every 17	
structure except the right hippocampus. In all regions, there were significant 18	
increases in atrophy rate (γ) after the change-point. This is demonstrated by 19	
deriving, from the results of the model, a ratio between the atrophy rate at EAO (1-0 20	
years before) to the pre-change atrophy rate. This ratio was 4.0 for whole brain, 4.5 21	
for ventricles, and 9.0 for left hippocampus, but it could not be produced for right 22	
hippocampus as the estimated pre-change atrophy rate was small and not 23	
statistically significantly different from zero. However, the increase in atrophy rate (γ) 24	
after the change-point for the right hippocampus was larger than the corresponding 25	
	 11	
coefficient in the results for the left hippocampus. The estimated change-point (d) for 1	
brain, ventricle and left hippocampus was 1.4 years before EAO and 1.1 years 2	
before EAO for the right hippocampus. For whole brain and left hippocampus, the 3	
confidence intervals for d did not span zero, providing evidence that they occurred 4	
before EAO. Estimates of the ventricular change-point had greater uncertainty (−1.1 5	
to 13.5 years) than the other structures. Table 2 provides estimates for rates of 6	
change at various times before and after EAO. 7	
	8	
As with the ‘step change’ model, in the ‘gradual acceleration’ model all structures 9	
except the right hippocampus had statistically significant pre-change atrophy rates. 10	
All regions had coefficients (γ) indicating statistically significant increased 11	
neurodegeneration after the change-point. The ratio of atrophy rate at EAO to the 12	
pre-change rate was 3.6 for whole brain, 4.1 for ventricles, and 5.1 for left 13	
hippocampus. The ratio for the right hippocampus was also not available due to the 14	
small, non-significant pre-change atrophy rate, but the coefficient (γ) indicated that 15	
the right hippocampus had a similar increase towards neurodegeneration as the left. 16	
The change-point estimates (d) for the whole brain and ventricles were 3.0-4.6 years 17	
earlier than for the hippocampi. For all structures, the confidence intervals for d did 18	
not span zero. Figure 2 shows estimated atrophy rates and 95% confidence intervals 19	
from both models in relation to EYO.  20	
 21	
In the sensitivity analysis, we re-ran the model including the participant with 22	
movement artefact and clinically implausible data (Supplementary Appendix B). The 23	
pattern of the results was not materially altered although the statistical significance of 24	
some parameter estimates was lost.  25	
	 12	
 1	
The estimated rates of change in sMut+ participants were approximately double 2	
those found in pMut+/qMut+ carriers at EAO using the change-point models. The 3	
symptomatic rates were: −2.41% (95% CI: −2.88, −1.95) per year for whole brain, 4	
15.0% (95% CI: 12.6,17.5) for ventricles, −4.70% (95% CI: −6.39, −3.01) for left 5	
hippocampus, and −4.64% (95% CI: −5.68, −3.60) for right hippocampus. 6	 	7	
4. Discussion  8	
The goal of this study was to estimate when brain, ventricular and hippocampal 9	
volume changes in ADAD diverge from non-carriers, and to model the rates before 10	
and after this transition using serial MRI data from the DIAN cohort.  We designed 11	
two non-linear mixed effects models: one assuming a single ‘step-change’ and 12	
another assuming a ‘gradual acceleration’ in rates of atrophy after the change-point. 13	
This type of model has previously been used to investigate the trajectories of 14	
cognitive decline [23,28] and atrophy rates [29,30]. In all cases, there was evidence 15	
of increased atrophy after the change-point, suggesting that our models better reflect 16	
the non-linear nature of atrophy in early-stage disease than a linear relationship 17	
would. The 'gradual acceleration' model found evidence for all assessed regions that 18	
atrophy rates diverge from normal values before symptom onset, with the change-19	
point occurring 3.0 to 7.6 years before EAO. The ‘step change’ model found a 20	
change-point of 1.4 years before EAO for whole brain and left hippocampus but was 21	
unable to show evidence of a change-point preceding EAO for ventricles or right 22	
hippocampus.  23	
 24	
4.1 Interpreting the change-point model results 25	
	 13	
A key advantage of using two different change-point models is that they provide 1	
complementary information about the timing of the change-point. The ‘step change’ 2	
model provides the most conservative estimate of when atrophy rates diverge. In 3	
contrast, the ‘gradual acceleration’ model is probably more biologically plausible, 4	
based on previous results in ADAD [4,7,31,32] and by the well-characterised spatial 5	
spread of neurodegeneration [33] that typically begins in the medial temporal lobe 6	
and gradually spreads into neocortical regions. However, there are caveats to the 7	
gradual acceleration model used. The non-linear nature of the atrophy may vary 8	
between individuals and a quadratic may not be the most appropriate fit. However, 9	
given the size of the dataset, this approach minimizes risk of overfittings. Change-10	
point models also avoid some of the pitfalls that can occur when including polynomial 11	
terms in a linear regression to model this non-linear relationship [34]. While a 12	
quadratic term could better capture the increase in atrophy rate observed around 13	
expected onset, it may also produce artefacts of increased atrophy in carriers who 14	
are decades before their expected onset. 15	
 16	
Unlike linear models, change-point models can capture the different phases of 17	
atrophy/expansion during the long period of presymptomatic disease progression. 18	
Both models provide similar estimates of β (see Table 2), the pre-change atrophy 19	
rate.  This suggested age-related changes broadly consistent with previous aging 20	
studies [35–37] showing small but significant rates of whole-brain atrophy of the 21	
order of 0.2-0.6%/year and hippocampal atrophy of the order of 0.3-0.4%/year for 22	
similar age ranges to this cohort.  From both models, there was evidence of 23	
increased atrophy after the change-point in all regions.  24	
 25	
	 14	
4.2 Estimating onset of pathological atrophy 1	
It is unclear when disease-related atrophy first becomes evident in ADAD. Cross-2	
sectional results from PSEN1 E280A mutation carriers [38,39] and DIAN [4,7] 3	
suggest atrophy of hippocampi diverge from non-carriers ~6 years and 10 years 4	
before symptom onset, respectively; earlier than in our models. However, initial 5	
longitudinal results from DIAN [7] (N=53) identified increased atrophy rates only in 6	
symptomatic carriers. A study of 13 presymptomatic PSEN1 carriers found increased 7	
cortical thickness at baseline but subsequent thinning of a number of cortical regions 8	
[40], suggesting a non-linear nature to presymptomatic changes – with grey matter 9	
increases preceding declines. 10	
 11	
Most previous longitudinal volumetric MRI studies of ADAD mutation carriers have 12	
been relatively small, single-site studies. One study following presymptomatic 13	
participants to clinical onset indicated pathological hippocampal atrophy rates 14	
appeared ~5.5 years before AD diagnosis [31]. Weston et al. [41] examined cortical 15	
thickness longitudinally in presymptomatic carriers and detected significant losses in 16	
the precuneus eight years before EAO. These values are consistent with our findings 17	
using a gradual acceleration model where the change point was 7.6 years before 18	
onset. However, another study of 16 ADAD mutation carriers (seven with long-term 19	
follow-up) did not detect structural MRI changes until after symptom onset [8], 20	
suggesting that a heterogeneity in these small cohorts and the methods used to 21	
analyze them may generate markedly different results.  22	
 23	
No prior ADAD study has used change-point models, making it difficult to compare 24	
estimates. However, there are similarities between our findings and sporadic AD 25	
	 15	
studies that used similar approaches. A study of 79 elderly patients, 37 of whom 1	
developed mild cognitive impairment (MCI), reported a ventricular expansion 2	
change-point 2.3 years before MCI diagnosis [29]. Another longitudinal study 3	
(N=296, 66 progressing to MCI) found a similar hippocampal atrophy change-point of 4	
2-4 years before clinical onset [30]. Their estimate of a 0.2% per year pre-change 5	
hippocampal atrophy rate accords with ours (0.2% left, 0.1% right). Their post-6	
change atrophy rate estimate for the right hippocampus (2.7%/year) was similar to 7	
our value (2.5%) whereas their left hippocampal rate estimate (1.2%) was lower than 8	
our (2.1%).  9	
 10	
4.3 Predicting clinical onset in ADAD 11	
An important challenge is what estimate to use for clinical onset before it has 12	
occurred. Many studies, including ours, use an EAO based on when the affected 13	
parent first developed symptoms consistent with progressive decline. Other 14	
measures are based on the average across all previously affected family members, 15	
or the reported age at onset in the literature for a particular mutation [3]. However, 16	
each is an imperfect estimate of the future age at onset.  17	
 18	
If future clinical trials use EYO as an inclusion criterion, then it is the distribution of 19	
atrophy rates relative to EAO that is of importance. However, if we wish to 20	
understand the etiology of the disease, then the distribution of atrophy rates relative 21	
to actual onset is more informative, as change-points are likely to be more strongly 22	
related to actual rather than expected age at onset. The effect of switching from 23	
actual to expected onset in statistical models will change the form of the estimated 24	
volume change over time, smoothing it to some degree. Without knowledge of actual 25	
	 16	
onset, this effect is not easily avoided. We did, however, attempt to reduce its impact 1	
by excluding overtly symptomatic carriers from our change-point models.  2	
 3	
Identifying precisely when clinical onset has occurred is not straightforward. To 4	
facilitate standardization across sites, DIAN rigorously monitors how raters perform 5	
CDR and other assessments [42].  In at-risk individuals, other factors can influence 6	
cognitive function or behavioral changes, including stress, anxiety, and the constant 7	
level of vigilance and introspection that participants experience. In this study, there 8	
were six qMut+ participants who reverted from a baseline global CDR of 0.5 to 0 at 9	
follow-up. These cases highlight the subtle nature of transitions from unimpaired to 10	
“affected” and the potential confounds of mood disturbance and other factors. We 11	
addressed this uncertainty by including questionably or mildly symptomatic carriers 12	
in our change-point models.  13	
 14	
4.4 Limitations and future work 15	
Change-point models have been used to model atrophy rates in preclinical sporadic 16	
AD [29,30]. We expand on these approaches by adapting the model for repeated 17	
measures of direct change instead of individual volumetric measures and allowing 18	
for either a ‘step change’ or ‘gradual acceleration’ after the change-point. Due to the 19	
non-linear nature of our models, and the use of bootstrapping to obtain confidence 20	
intervals for the model coefficients, these models are susceptible to influential 21	
outliers, especially with smaller sample sizes (see the sensitivity analysis in 22	
Supplementary Appendix B). Additional longitudinal data should provide improved 23	
robustness against such issues.  24	
 25	
	 17	
No prior study has characterized the progression of atrophy in such a large cohort of 1	
presymptomatic and earliest symptomatic ADAD. DIAN is currently recruiting 2	
participants into a multicentre clinical trial [43], and the samples from our analysis 3	
should more closely reflect a clinical trial setting. Whole brain, lateral ventricles, and 4	
hippocampi are the most studied structures in sporadic AD, and are often used as 5	
trial outcome measures. From the results, these atrophy measures appear to be 6	
elevated compared to non-carriers approximately 5 years before expected onset, 7	
making them best suited for prevention trials in ADAD from this period onward. 8	
Given the evidence of presymptomatic atrophy in specific cortical regions [40,41], 9	
future application of the change-point model could involve studying atrophy rates of 10	
specific cortical structures, such as the precuneus and posterior cingulate. Atrophy in 11	
these structures may appear earlier and thus be better suited for trials that target 12	
presymptomatic patients.  In addition, the model should incorporate information from 13	
other biomarkers, including CSF amyloid and tau concentrations, to determine how 14	
markers of these pathologies affect the timing of the change-point. Finally, it is 15	
essential to understand which preclinical changes in ADAD generalize to sporadic 16	
AD, as differences in the structures preferentially affected appear to exist [44].  17	
 18	
4.5 Conclusions 19	
Atrophy rates increase in ADAD some years before expected symptom onset. Using 20	
two different change-point models, we can characterize when this change occurs. 21	
The ‘step-change’ model provides a minimum estimate, 1.4 years before expected 22	
onset. The ‘gradual acceleration’ model provides a more biologically plausible 23	
approach towards how atrophy rates diverge from normal, with brain atrophy rates 24	
showing pathological acceleration ~7.6 years before expected onset and 25	
	 18	
hippocampal rates changing ~3.0 years before expected onset. These models may 1	
help predict the time to clinical onset for presymptomatic individuals with increased 2	
atrophy and identify individuals for prevention trials.  3	
	 19	
Figure captions 1	
 2	
Figure 1: Schematic representation of the ‘step change’ (Figure 1a) and 3	
‘gradual acceleration’ (Figure 1b) change-point models. 4	
 5	
Figure 2: Rates of change estimated from the ‘step change’ and ‘gradual 6	
acceleration’ models, as a function of the estimated years from symptom 7	
onset (EYO) for the pMut+/qMut+ carriers. 8	
The figure shows the relationship between rate of annualized volume change (%) 9	
and EYO. 95% confidence intervals are included, computed from the bootstrap 10	
samples. While the schematics in Figure 1 display the decline in actual volume, 11	
these graphs represent the rate of change in volume. A horizontal line indicates the 12	
estimated atrophy rate (from the ‘step change’ model) for non-carriers and carriers 13	
before the change-point before any deviation from normal rates of change. Vertical 14	
dotted lines indicate the change-points for both the ‘step change’ and ‘gradual 15	
acceleration’ models. For periods that include the change-point, the estimated rate of 16	
atrophy is a weighted combination representing the transition from the pre-change-17	
point atrophy to the post-change-point atrophy. Top left: whole brain; top right: lateral 18	
ventricles; bottom left: left hippocampus; bottom right: right hippocampus.  19	
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